, Tracking Stock Market Picks
Enter Symbol:
Cytori Therapeutics Inc (CYTX) [hlAlert]

down 94.63 %

Cytori Therapeutics Inc (CYTX) rated Buy

Posted on: Wednesday,  Dec 12, 2007  8:25 AM ET by Broadpoint Capital

Broadpoint Capital rated Buy Cytori Therapeutics Inc (NASDAQ: CYTX) on 12/12/2007, when the stock price was $5.59. Since
then, Cytori Therapeutics Inc has lost 94.63% as of 09/08/2015's recent price of $0.30.
If you would have followed this Broadpoint Capital's recommendation on CYTX, you would have lost 94.63% of your investment in 2827 days.

Cytori Therapeutics, Inc. develops, manufactures, and sells medical technologies to enable the practice of regenerative medicine. The Company?s commercial activities are focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, and stem and regenerative cell banking (cell preservation) in worldwide. Its product pipeline includes the development of new treatments for cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease and pelvic health conditions. The Company?s Celution System family of products processes patients? cells at the bedside in real time. During the year ended December 31, 2008, the Celution 800/CRS System was introduced into the European cosmetic and reconstructive surgery market through a network of medical distributors. The Celution 900/MB is marketed in Japan through its commercialization partner, Green Hospital Supply, Inc.

Broadpoint Capital, Inc. is an investment banking and capital markets firm that provides corporate and public finance services and trading of corporate, government, and municipal securities for institutions. The company has three divisions: Municipal Capital Markets division, which underwrites and trades municipal securities in new issue and secondary markets; Taxable Fixed Income division, which is a dealer focusing on fixed income securities with limited liquidity; and Equity Capital Markets division, which is a sector-focused investment banking group providing research, trading, raising of capital and advisory services for institutional and corporate clients. Broadpoint Capital, formerly known as First Albany Corporation, was founded in 1953 and is based in New York, New York. The company operates as a subsidiary of First Albany Companies Inc.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/12/2007 8:25 AM Buy
as of 8/27/2015
1 Week down  -28.57 %
1 Month down  -53.12 %
3 Months down  -55.88 %
1 YTD down  -88.32 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy